A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Phase 1 Completed 64 enrolled Suven Life Sciences Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-D4010 in healthy male subjects following single or multiple ascending doses.

Timeline

Start: 2015-07
Primary completion: 2016-02
Completion: 2016-06

Publications

Nirogi R, Bhyrapuneni G, Muddana NR, Goyal VK, Pandey SK, Mohammed AR, Ravula J, Jetta S, Palacharla VRC. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects. Clin Drug Investig. 2021 May;41(5):469-482. doi: 10.1007/s40261-021-01027-4. Epub 2021 Mar 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SUVN-D4010	Small molecule	25 mg	Oral
Subject	SUVN-D4010	Small molecule	40 mg	Oral
Subject	SUVN-D4010	Small molecule	45 mg	Oral

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications